No Data
No Data
ADC Therapeutics Is Maintained at Overweight by Stephens & Co.
Stephens Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Raises Target Price to $8
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics Achieves Profitability With ZYNLONTA
Express News | HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target
Positive Buy Rating Driven by Promising ADC Therapeutics Trial and Financial Projections
Unlock the Full List